LWAY earnings analysis
What we found in LWAY's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, segment results, or MD&A, so current-period financial metrics cannot be determined from the provided filing text. It reports effective disclosure controls as of June 30, 2026 and no material internal-control changes. The filing also discloses a June 30, 2026 secured funding agreement and a May offering involving 3,454,756 shares, alongside a 253,153-share repurchase at $19.50 per share.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls assessed effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, with the evaluation performed by the CEO and CFO.
- Share repurchase completed
- The company repurchased 253,153 shares at $19.50 per share during fiscal year 2026, according to the issuer-purchase table.
- Offering and repurchase disclosed
- The May 19, 2026 offering involved 3,454,756 shares sold by Danone USA Public Benefit Corporation at $19.50 per share; Lifeway repurchased 253,153 shares in the offering.
- No material control changes
- The company reported no changes during the quarter that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- New secured funding arrangement
- The company entered into a Master Security Agreement, Interim Funding Agreement, and Equipment Guidance Line Note with CIBC Bank USA dated June 30, 2026. The supplied excerpt does not disclose the facility amount or outstanding balance.
- Cash used for share repurchase
- Lifeway repurchased 253,153 shares at $19.50 per share in connection with the offering, representing approximately $4.9 million of share purchases based on the disclosed price and share count.
- No updated risk-factor disclosures
- The filing states there were no material changes from the risk factors in the 2025 Form 10-K, so no newly identified risk-factor changes are disclosed in the supplied text.
What they said about what is next.
The supplied 10-Q text does not provide quantitative revenue or EPS guidance. Prior full-year revenue guidance of $250 million to $260 million was reported in the prior analysis, but its status is not stated in the supplied filing excerpt.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- Lifeway Foods, Inc. reported a notable increase in Q1 2026 revenue to $63.0 million, a 36.7% increase from $46.1 million in Q1 2025. The diluted EPS rose to $0.31, surpassing both the prior year’s EPS of $0.23 and…
- 10-K · March 17, 2026
- Lifeway reports record net sales of $212,496,000 in 2025, up from $186,820,000 in 2024, driven by its core drinkable kefir franchise which represented 85% of 2025 net sales ($181,423,000). The company emphasizes product…
- 10-Q · November 14, 2024
- Lifeway reported quarterly revenue of $46,095,000 (three months ended September 30, 2024), up from $40,896,000 a year ago, while diluted EPS declined to $0.19 from $0.23. Operating income fell to $4,189,000 from…
- 10-Q · August 13, 2024
- Lifeway reported a strong quarter ended June 30, 2024 with net sales of $49,157 (three months) vs $39,230 a year ago (+$9,927, +25.3%) and income from operations of $5,386. Profitability and EPS improved versus the…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LWAY makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever